Antiretroviral drugs

被引:142
作者
De Clercq, Erik [1 ]
机构
[1] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium
关键词
REVERSE-TRANSCRIPTASE INHIBITORS; RESISTANT HIV-1 INFECTION; TREATMENT-NAIVE PATIENTS; RALTEGRAVIR RESISTANCE; COMBINATION THERAPY; IN-VIVO; VIRUS; MUTATIONS; DISCOVERY; INVITRO;
D O I
10.1016/j.coph.2010.04.011
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In October 2010, it will be exactly 25 years ago that the first antiretroviral drug, AZT (zidovudine, 3'-azido-2',3'dideoxythymidine), was described. It was the first of 25 antiretroviral drugs that in the past 25 years have been formally licensed for clinical use. These antiretroviral drugs fall into seven categories [nucleoside reverse transcriptase inhibitors (NRTIs), nucleotide reverse transcriptase inhibitors (NtRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (Pls), fusion inhibitors (Fls), co-receptor inhibitors (CRIs) and integrase inhibitors (INIs). The INIs (i.e. raltegravir) represent the most recent advance in the search for effective and selective anti-HIV agents. Combination of several anti-HIV drugs [often referred to as highly active antiretroviral therapy (HAART)] has drastically altered AIDS from an almost uniformly fatal disease to a chronic manageable one.
引用
收藏
页码:507 / 515
页数:9
相关论文
共 44 条
[41]   Entry inhibitors in the treatment of HIV-1 infection [J].
Tilton, John C. ;
Doms, Robert W. .
ANTIVIRAL RESEARCH, 2010, 85 (01) :91-100
[42]   Lack of a significant drug interaction between raltegravir and tenofovir [J].
Wenning, Larissa A. ;
Friedman, Evan J. ;
Kost, James T. ;
Breidinger, Sheila A. ;
Stek, Jon E. ;
Lasseter, Kenneth C. ;
Gottesdiener, Keith M. ;
Chen, Joshua ;
Teppler, Hedy ;
Wagner, John A. ;
Stone, Julie A. ;
Iwamoto, Marian .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (09) :3253-3258
[43]   Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance [J].
Wensing, Annemarie M. J. ;
van Maarseveen, Noortje M. ;
Nijhuis, Monique .
ANTIVIRAL RESEARCH, 2010, 85 (01) :59-74
[44]   Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug [J].
Wirden, Marc ;
Simon, Anne ;
Schneider, Luminita ;
Tubiana, Roland ;
Malet, Isabelle ;
Ait-Mohand, Hocine ;
Peytavin, Gilles ;
Katlama, Christine ;
Calvez, Vincent ;
Marcelin, Anne-Genevieve .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (05) :1087-1090